X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs CADILA HEALTHCARE - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS CADILA HEALTHCARE NOVARTIS/
CADILA HEALTHCARE
 
P/E (TTM) x 349.6 34.3 1,018.2% View Chart
P/BV x 17.2 8.8 194.6% View Chart
Dividend Yield % 1.7 0.7 242.3%  

Financials

 NOVARTIS   CADILA HEALTHCARE
EQUITY SHARE DATA
    NOVARTIS
Mar-16
CADILA HEALTHCARE
Mar-16
NOVARTIS/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs982454 216.1%   
Low Rs556305 182.7%   
Sales per share (Unadj.) Rs252.996.1 263.2%  
Earnings per share (Unadj.) Rs62.114.9 417.8%  
Cash flow per share (Unadj.) Rs63.317.8 355.1%  
Dividends per share (Unadj.) Rs10.003.20 312.5%  
Dividend yield (eoy) %1.30.8 154.2%  
Book value per share (Unadj.) Rs363.652.3 695.6%  
Shares outstanding (eoy) m31.961,023.74 3.1%   
Bonus/Rights/Conversions -FV5:1-  
Price / Sales ratio x3.03.9 77.0%   
Avg P/E ratio x12.425.5 48.5%  
P/CF ratio (eoy) x12.221.3 57.1%  
Price / Book Value ratio x2.17.3 29.1%  
Dividend payout %16.121.5 74.8%   
Avg Mkt Cap Rs m24,580388,458 6.3%   
No. of employees `0000.815.4 4.9%   
Total wages/salary Rs m1,80113,317 13.5%   
Avg. sales/employee Rs Th10,748.96,371.1 168.7%   
Avg. wages/employee Rs Th2,395.2862.4 277.7%   
Avg. net profit/employee Rs Th2,641.1986.1 267.8%   
INCOME DATA
Net Sales Rs m8,08398,376 8.2%  
Other income Rs m829941 88.1%   
Total revenues Rs m8,91399,317 9.0%   
Gross profit Rs m23423,829 1.0%  
Depreciation Rs m373,022 1.2%   
Interest Rs m2486 0.4%   
Profit before tax Rs m1,02521,262 4.8%   
Minority Interest Rs m0-300 0.0%   
Prior Period Items Rs m175 334.0%   
Extraordinary Inc (Exp) Rs m1,696-25 -6,785.2%   
Tax Rs m7525,716 13.2%   
Profit after tax Rs m1,98615,226 13.0%  
Gross profit margin %2.924.2 12.0%  
Effective tax rate %73.426.9 272.9%   
Net profit margin %24.615.5 158.8%  
BALANCE SHEET DATA
Current assets Rs m12,67844,376 28.6%   
Current liabilities Rs m2,43334,071 7.1%   
Net working cap to sales %126.710.5 1,209.9%  
Current ratio x5.21.3 400.1%  
Inventory Days Days3354 60.7%  
Debtors Days Days2262 36.1%  
Net fixed assets Rs m6947,896 0.1%   
Share capital Rs m1601,024 15.6%   
"Free" reserves Rs m11,46048,746 23.5%   
Net worth Rs m11,62153,519 21.7%   
Long term debt Rs m08,964 0.0%   
Total assets Rs m14,400100,163 14.4%  
Interest coverage x570.544.7 1,274.9%   
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x0.61.0 57.2%   
Return on assets %13.815.7 88.0%  
Return on equity %17.128.4 60.1%  
Return on capital %23.634.3 68.7%  
Exports to sales %0.745.3 1.6%   
Imports to sales %18.65.9 313.3%   
Exports (fob) Rs m6044,537 0.1%   
Imports (cif) Rs m1,5035,838 25.7%   
Fx inflow Rs m18644,881 0.4%   
Fx outflow Rs m1,8219,069 20.1%   
Net fx Rs m-1,63535,812 -4.6%   
CASH FLOW
From Operations Rs m2,53119,938 12.7%  
From Investments Rs m-8,270-9,039 91.5%  
From Financial Activity Rs m-386-9,527 4.0%  
Net Cashflow Rs m-6,1251,372 -446.4%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 8.3 24.1%  
FIIs % 1.6 5.9 27.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 11.0 195.5%  
Shareholders   41,647 44,069 94.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   PIRAMAL ENTERPRISES  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  ABBOTT INDIA  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 23, 2017 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS